Navigation Links
Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial
Date:5/4/2009

ey at its TGA-approved manufacturing facilities. For more information about Pharmaxis, go to http://www.pharmaxis.com.au or contact Investor Relations on phone +61 2 9454 7200.

About Bronchitol

Pharmaxis Ltd is developing Bronchitol for the management of chronic obstructive lung diseases including cystic fibrosis, and bronchiectasis. Bronchitol is a proprietary dry-powder mannitol, precision formulated for delivery to the lungs through an easy-to-use, pocket-size, portable inhaler. Once inhaled its action on mucus helps restore normal lung clearance mechanisms. Clinical studies have shown Bronchitol to be effective and well tolerated in stimulating mucus hydration and clearance in people with chronic obstructive lung diseases. In particular, Bronchitol has been shown to increase mucus clearance from the lungs and significantly improve quality of life for people with bronchiectasis. Additional studies have also shown Bronchitol to improve lung function in people affected by cystic fibrosis.

About Cystic Fibrosis

In a healthy person, there is a constant flow of mucus over the surfaces of the air passages in the lungs, removing debris and bacteria. In CF, an inherited disease, a defective gene disrupts ion transport across the epithelial membrane within cells. In the lungs, this leads to a depletion of the airway surface liquid that normally bathes the cilia, and a resultant reduction in mucociliary clearance. The result is thick, sticky mucus that clogs the lungs, severely restricting the natural airway-clearing process. It also increases the potential for bacteria to become trapped and for inflammation, thus creating an unhealthy lung environment that leads to life- threatening lung infections.

Forward-Looking Statements

The statements contained in this media release that are not purely historic
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
2. Pharmaxis Announces New Drug Application Submission for Aridol(TM)
3. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
4. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
5. Pharmaxis Establishes Named Patient Program for Bronchitol
6. Pharmaxis Long-Term Safety Study of Bronchitol Completes
7. Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
8. Optherion Announces Issuance of Canadian Patents Covering Age-Related Macular Degeneration Diagnostics and Treatments
9. Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study
10. Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
11. Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ... of its lead molecule, Anatabine Citrate, in ... Clinical, The Translational Pharmaceutics Company, based in the ... early development programs. The Company expects to ... of the third quarter with the Medicines Healthcare products ...
(Date:7/31/2014)... 31, 2014 Touro University California,s College of ... as the recipient of a $150,000 grant by the ... University to increase research and classroom space on its ... for the study of health sciences, and will help ... and interests of our students," said Shelley Berkley ...
(Date:7/31/2014)... July 31, 2014 Catylix, Inc. ( ... ( Milpitas, California ) announced today ... and commercialize new fluorination products and related chemistry. ... benefited from the use of substituents that are ... with polarity to improve binding and bioavailability. Fluorinated ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Touro University California Garners Grant From Long Foundation 2Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2
... mental retardation, birth defects, and autism spectrum and ... in New YorkMADISON, N.J., March 17 Quest ... world,s leading provider of diagnostic testing, information and ... genomic hybridization (aCGH) postnatal test is now available ...
... Inc. announced today that it has achieved proof ... Inhibiting Multiple Pathways) kinase platform by designing a ... of both the PI3K (Phosphoinositide-3-kinase) pathway and the ... SF2626 has demonstrated the ability to inhibit both ...
Cached Medicine Technology:Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State 2Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State 3Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State 4Semafore Achieves a Preclinical Milestone with SF2626, a PI3K-MEK Dual Pathway Kinase Inhibitor 2
(Date:8/1/2014)... 01, 2014 Over 20,000 entrepreneurs from ... the 2014 Market America | SHOP.COM International Convention at ... The annual event will introduce new products, technology, programs ... earning, and also feature a who’s who of celebrities. ... | SHOP.COM Executive Team, successful entrepreneurs and celebrity guests. ...
(Date:8/1/2014)... FL (PRWEB) August 01, 2014 Fitness is ... too much effort. From walking around the block to biking ... to do and easy to maintain throughout the year. The ... a fitness forward series which will feature special guests, tips ... and stay in shape. The series will air on most ...
(Date:8/1/2014)... August 01, 2014 We are ... ES-AMI on AWS Marketplace. EspressReport ES-AMI delivers enterprise ... at $0.50 per hour (AWS infrastructure charges apply). ... easy-to-use enterprise BI and operational reporting system with ... and ad hoc reporting. It allows users to ...
(Date:8/1/2014)... Register to join the webinar here: http://bit.ly/1lPZNI9 . ... record for life sciences investing. IPOs in the sector tripled ... all venture dollars spent in 2013. The result: biotech companies ... However, 2014 is proving more of a mixed bag of ... while life sciences IPOs are losing steam, M&A is expected ...
(Date:7/31/2014)... Serious buyer, Andrew Hawley, announces his search ... Owsley Bear Stanley, the King of Acid, created the ... to Hawley, “The Grateful Dead and Owsley teamed up ... San Francisco and Los Angeles in 1965. The 1965 ... of paper. They were a goldenrod yellow, blue, and ...
Breaking Medicine News(10 mins):Health News:Market America | SHOP.COM Set to Unveil Technology Enhancements and New Products at the 2014 International Convention 2Health News:Market America | SHOP.COM Set to Unveil Technology Enhancements and New Products at the 2014 International Convention 3Health News:Market America | SHOP.COM Set to Unveil Technology Enhancements and New Products at the 2014 International Convention 4Health News:Market America | SHOP.COM Set to Unveil Technology Enhancements and New Products at the 2014 International Convention 5Health News:Forbes Living to Air Fitness Forward Series 2Health News:Quadbase Systems Inc. Announces The Availability Of It’s Flagship Enterprise Reporting, Dashboard and BI Analytics Tool on Amazon’s AWS Marketplace 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 3
... surgeon John J. Callaghan, MD was elected to the Board ... ( http://www.aaos.org/ )(AAOS) at the organization,s 2009 Annual Meeting ... First Vice-President.Having to wear a cast as a young child, ... the field of orthopaedic surgery. "Breaking my arm taught ...
... time for ACL injuries in young athletesLAS VEGAS, Feb. ... Ligament (ACL) tears occur in the United States. ... Meeting of the American Academy of Orthopaedic Surgeons ... seen in younger patients as an increasing number of ...
... 25 February 2009 Molecular Oncology ... behalf of the Federation of European Biochemical Societies ... ISI), for inclusion in the Science Citation Index ... , MOLONC (published 6 times a year ...
... 25 The National Hospice and Palliative Care Organization ... Out" grants. Funded by the Department of Veterans Affairs, ... hospice and palliative care services for rural and homeless ... represent a range of community-based organizations. These providers ...
... Products Completely Safe, Include No Ingredients from PCA -NEW YORK, ... not affected by the Peanut Corporation of America (PCA) recall, ... any variety of KIND Fruit + Nut Bars or KIND ... that PCA is the focus of their investigation concerning a ...
... intergenerational program developed by OASIS to enlist older adults ... to eight cities during the next two years with ... promotes physical activity and healthy eating for low-income children ... grades 3 to 5 in after-school settings using teams ...
Cached Medicine News:Health News:John J. Callaghan, MD Elected Academy First Vice President 2Health News:John J. Callaghan, MD Elected Academy First Vice President 3Health News:An Athlete's First Question: 'Doc, When Can I Return?' 2Health News:An Athlete's First Question: 'Doc, When Can I Return?' 3Health News:Molecular Oncology accepted into Thomson Reuters index 2Health News:Grants to Increase Access to Hospice and Palliative Care for Rural and Homeless Veterans Awarded by National Hospice and Palliative Care Organization 2Health News:KIND Snacks Unaffected by Peanut Butter Recall 2Health News:WellPoint Foundation Awards Grants to OASIS to Expand Unique Active Generations Program 2Health News:WellPoint Foundation Awards Grants to OASIS to Expand Unique Active Generations Program 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: